IL162929A0 - Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization - Google Patents

Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Info

Publication number
IL162929A0
IL162929A0 IL16292903A IL16292903A IL162929A0 IL 162929 A0 IL162929 A0 IL 162929A0 IL 16292903 A IL16292903 A IL 16292903A IL 16292903 A IL16292903 A IL 16292903A IL 162929 A0 IL162929 A0 IL 162929A0
Authority
IL
Israel
Prior art keywords
lasofoxifene
recrystallization
purification
purified
racemic
Prior art date
Application number
IL16292903A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL162929A0 publication Critical patent/IL162929A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16292903A 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization IL162929A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36887202P 2002-03-28 2002-03-28
PCT/IB2003/001033 WO2003082814A1 (en) 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Publications (1)

Publication Number Publication Date
IL162929A0 true IL162929A0 (en) 2005-11-20

Family

ID=28675551

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16292903A IL162929A0 (en) 2002-03-28 2003-03-17 Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
IL162929A IL162929A (en) 2002-03-28 2004-07-08 Methods of purifying sophisticated sufoxifen by reconstitution

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162929A IL162929A (en) 2002-03-28 2004-07-08 Methods of purifying sophisticated sufoxifen by reconstitution

Country Status (23)

Country Link
US (2) US6906202B2 (xx)
EP (1) EP1487790B1 (xx)
JP (1) JP4268055B2 (xx)
KR (1) KR100636953B1 (xx)
CN (1) CN1283625C (xx)
AR (1) AR039152A1 (xx)
AT (1) ATE459599T1 (xx)
AU (1) AU2003209603B2 (xx)
BR (1) BR0308758A (xx)
CA (1) CA2479924C (xx)
DE (1) DE60331527D1 (xx)
DK (1) DK1487790T3 (xx)
ES (1) ES2339936T3 (xx)
HK (1) HK1073111A1 (xx)
HU (1) HUP0500025A3 (xx)
IL (2) IL162929A0 (xx)
MX (1) MXPA04009259A (xx)
PL (1) PL372727A1 (xx)
RS (1) RS80604A (xx)
RU (1) RU2278861C2 (xx)
TW (1) TW200306974A (xx)
WO (1) WO2003082814A1 (xx)
ZA (1) ZA200405209B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487790B1 (en) * 2002-03-28 2010-03-03 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CN102311406A (zh) * 2010-06-29 2012-01-11 武汉启瑞药业有限公司 拉索昔芬中间体的制备方法
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Er+乳がんのラソフォキシフェン処置
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
KR102412089B1 (ko) 2021-09-13 2022-06-22 주식회사 세라수 Dmts의 정제방법
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
KR102663941B1 (ko) 2024-03-04 2024-05-08 주식회사 세라수 Drometrizole trisiloxane(DMTS)의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326865A (en) * 1990-06-08 1994-07-05 Hercules Incorporated Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
EP0756205A3 (en) * 1995-07-26 1998-10-14 Eastman Kodak Company Pattern transfer techniques for fabrication of lenslet arrays using specialized polyesters
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6180375B1 (en) 1999-08-27 2001-01-30 Pfizer Inc. Microbial biotransformation
OA12596A (en) 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
EP1487790B1 (en) * 2002-03-28 2010-03-03 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization

Also Published As

Publication number Publication date
HUP0500025A3 (en) 2005-10-28
AR039152A1 (es) 2005-02-09
JP2005521727A (ja) 2005-07-21
US7358374B2 (en) 2008-04-15
ES2339936T3 (es) 2010-05-27
US6906202B2 (en) 2005-06-14
JP4268055B2 (ja) 2009-05-27
ZA200405209B (en) 2005-08-31
DK1487790T3 (da) 2010-05-10
EP1487790A1 (en) 2004-12-22
HK1073111A1 (en) 2005-09-23
RU2278861C2 (ru) 2006-06-27
CA2479924C (en) 2008-07-15
US20050171189A1 (en) 2005-08-04
CA2479924A1 (en) 2003-10-09
KR20040108693A (ko) 2004-12-24
EP1487790B1 (en) 2010-03-03
CN1283625C (zh) 2006-11-08
DE60331527D1 (de) 2010-04-15
ATE459599T1 (de) 2010-03-15
MXPA04009259A (es) 2005-01-25
BR0308758A (pt) 2004-12-28
RS80604A (xx) 2007-02-05
WO2003082814A1 (en) 2003-10-09
AU2003209603B2 (en) 2008-07-17
RU2004128931A (ru) 2005-04-10
US20030212122A1 (en) 2003-11-13
HUP0500025A2 (hu) 2005-04-28
IL162929A (en) 2009-11-18
KR100636953B1 (ko) 2006-10-19
PL372727A1 (en) 2005-07-25
TW200306974A (en) 2003-12-01
CN1625548A (zh) 2005-06-08
AU2003209603A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
HK1073111A1 (en) Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
HK1158223A1 (en) Purification of anti-her2 antibodies -2 (her-2)
AU2003297844A1 (en) Methods for reducing latency of a call set up
HK1082173A1 (en) Generalized metronome for modification of biorhythmic activity
EP1777196A4 (en) METHOD OF PURIFYING SILICON AND PURIFIED SILICON USING THE SAME
PT1590061E (pt) Método para purificação de alfa-1-antitripsina
SI1578695T1 (sl) Postopek za odstranitev biofilma
IL195370A0 (en) A crystallization method for purification of calcipotriene
PL376604A1 (pl) Polimorfy chlorowodorku bicifadyny
HUP0302444A2 (hu) Eljárás nitrogéntartalmú heterociklusos vegyületek monometilezésére
AU2003215781A8 (en) Method for production of phytoalexins
IL166592A0 (en) Novel crystalline forms of gatifloxacin
IL165115A0 (en) Novel crystalline forms of gatifloxacin
EP1512783A4 (en) KNITTING METHOD
TWI347932B (en) Producing method of purified 2-cyanoacrylates
AU2003280968A8 (en) Method of synthesis of carbon nanomaterials
GB0224049D0 (en) Removal of nitrogen compounds
PL353509A1 (en) Method of purification of 5-aminolevulline acid hydrochloride
IL165690A0 (en) Novel crystalline forms of gatifloxacin
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003258982A8 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound
AU2003243153A8 (en) Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
EP1511474A4 (en) Methods of Treatment
AU2003270107A1 (en) Purification method for fredericamycin a
GB0228795D0 (en) Improvement to a device for correction of distortion